Secondly, using the double labelling of CD16/CD62L originally described by the Koenderman group (35), we showed that the major CD16high/CD62Lhigh subpopulation in healthy donors, was decreased in CF patients both when clinically stable and during exacerbations. This evidence concerns the gene SELL and cystic fibrosis.